Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 22, 2020

SELL
$34.58 - $48.06 $127,842 - $177,677
-3,697 Closed
0 $0
Q3 2019

Oct 22, 2019

BUY
$36.98 - $48.45 $136,715 - $179,119
3,697 New
3,697 $137,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Convergence Investment Partners, LLC Portfolio

Follow Convergence Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Convergence Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Convergence Investment Partners, LLC with notifications on news.